ATR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AptarGroup Inc (ATR) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock lacks immediate positive catalysts, and its financial performance shows declining profitability despite revenue growth. While analysts have recently upgraded the stock and raised price targets, the technical indicators and options data do not suggest a strong entry point right now. Holding or waiting for a better opportunity is recommended.
The MACD is positive and expanding, indicating a slightly bullish momentum. However, the RSI is neutral at 51.77, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 124.45, with resistance at 127.632 and support at 121.268. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Analysts have recently upgraded the stock, with Wells Fargo raising its rating to Overweight and increasing the price target to $
The company has a strong balance sheet and significant exposure to the defensive pharma sector, which is favorable during uncertain periods.
Financial performance in Q4 2025 shows a decline in net income (-26.35% YoY), EPS (-23.65% YoY), and gross margin (-12.01% YoY), indicating profitability challenges.
No recent news or significant trading trends from hedge funds or insiders.
Technical indicators and options data do not signal strong bullish sentiment.
In Q4 2025, revenue increased by 13.52% YoY to $962.7M, but net income dropped by 26.35% YoY to $74.34M. EPS declined by 23.65% YoY to 1.13, and gross margin fell by 12.01% to 27.18%. The company is experiencing growth in revenue but declining profitability.
Recent analyst ratings are positive, with Wells Fargo upgrading the stock to Overweight and raising the price target to $144. Baird also raised its price target to $156, citing improved earnings visibility. However, BofA maintains a Neutral rating with a price target of $147, highlighting intermediate-term challenges such as litigation and sluggish trends in certain segments.
